Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
about
Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials.Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical TrialsRole of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab.Psoriasis and Psoriatic Arthritis.Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab.Raising Standards for the Evaluation of Future Psoriasis Therapeutics: A Critical Checklist.The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis.Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy.Infections from 7 Clinical Trials of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, in Patients with Moderate-to-Severe Psoriasis.The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies.Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3.Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: a meta-analysis from phase 3 randomized controlled trials.Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practiceChronic Pruritus: Current and Emerging Treatment Options.IL-17 Signaling: The Yin and the Yang.Tildrakizumab for treating psoriasis.Apremilast for the management of moderate to severe plaque psoriasis.Affibody molecules as engineered protein drugs.Biomaterial strategies for generating therapeutic immune responses.Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease.Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications.EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1).Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, Phase 3 NAVIGATE trial.Autoreactive T Cells and Chronic Fungal Infection Drive Esophageal Carcinogenesis.Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case reportClinical efficacy and IL-17 targeting mechanism of Indigo naturalis as a topical agent in moderate psoriasis.Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy.Inhibition of autoimmune Th17 cell responses by pain killer ketamine.Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.Drug survival of biologic treatments in psoriasis: a systematic review.Review of IL-17 inhibitors for psoriasis.Limited Presence of IL-22 Binding Protein, a Natural IL-22 Inhibitor, Strengthens Psoriatic Skin Inflammation.T helper type 17 cells in immune-mediated glomerular disease.Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants.Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
P2860
Q33625546-242DA1BB-5C9B-4F53-889A-E2D6B6AAD892Q36190962-71B862D0-B26E-452B-A03A-B6AB7A81C142Q37712237-7A446A12-7D78-47A4-9AF3-DB9F3CEE653DQ37723047-1C4A7D57-9BB9-4A3D-875F-25227B12F25BQ38632525-F9663B8F-B8BF-4E42-8C3F-32E23FEED3F9Q38658837-95BA7D51-7060-4C15-8A49-BAAAC7700FF7Q38707588-E061848D-3EDD-4E8D-BA39-77FC02A7824DQ38707920-23F131A3-DE87-475D-AF0A-F62FCF00D031Q38732809-5211EFFD-01B4-44B2-883C-86E3FC936CBDQ38733182-580C9629-2F25-4549-A2DB-393A38C869DEQ38764716-427E10D2-25CB-4590-A4F6-64AA9C1D606AQ38907492-7EAB0089-203E-405E-A5A4-D4E12E065FDFQ38965214-1A2170F5-9412-49D2-B6E3-83715D636236Q38969026-8860D4AD-4515-4ABE-93CA-B24A572465FDQ38990571-1C37A912-4F11-4AFD-9F5F-8A8409BA4F7FQ39096719-06C40CC5-884E-49BB-A393-291A43B86127Q39153776-03EF8276-D863-43D2-B2D5-329D362A9E72Q39156148-5EC57073-2259-4E64-BD37-20562E70C5C3Q39158530-A8D60887-AF35-44B2-BC61-54D653707BE2Q39167757-D2282835-E696-4B18-BFF7-A69F2FFEA10EQ39170240-707420D0-E7D7-4DAF-8756-7BAE3D6EF40BQ39197528-2B39FA11-5775-4FCD-80E6-CD04DE19319FQ39271088-F35B5CC3-AA92-47EF-9C08-073F8C07074AQ39315997-794F17D3-F75B-4C5F-B348-18E0F9E71BBDQ39376982-579C2989-5E1C-438B-A90C-683578BDEEEAQ39546109-DD8F8BB8-5E2F-4273-A153-73BFB2E42103Q40164166-914A5644-EACA-4DC2-BCBC-67ACD3DB9551Q40164172-26C2D37C-F937-4895-AF0E-44D72A13D22BQ40251957-3BFEE8BA-5A8E-4265-AE02-BB68785FBEF0Q41018488-35BCEEBC-0BA5-4014-858A-08A7CB843ADAQ41594843-8EB9CEB2-7737-4297-9EFD-DE01DAB4F4D1Q41861093-37959008-344B-4B1D-B2F0-EB3B43F3A4C2Q45390339-64BBE027-99C7-430A-A3C5-2E6A9189C8DFQ45977850-8ACE2158-0BDA-4371-9E57-2B3A2D558038Q46118586-738B4419-1ACA-4366-87AF-7CC9AAAA916BQ46131367-21D5AA11-6B27-4829-A928-42507D602791Q46239692-5CEA8E31-9DF9-461C-A027-4C7936B73557Q46325099-4DBC91A1-9D06-49F5-BE7C-453170A563EBQ47143243-AA6A20F3-39C3-4463-963B-9C084F684F9FQ47260366-FDB4C0F7-A5B5-44CD-9F78-9E7635C6CC16
P2860
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
@en
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
@nl
type
label
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
@en
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
@nl
prefLabel
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
@en
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
@nl
P2093
P356
P1476
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
@en
P2093
Andrew Blauvelt
Brian J Nickoloff
Craig L Leonardi
Daniel K Braun
David Amato
Fangyi Zhao
Gregory S Cameron
Janelle Erickson
Kenneth B Gordon
Kristian Reich
P304
P356
10.1056/NEJMOA1512711
P407
P577
2016-06-08T00:00:00Z